ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2021 - 2025)
ProQR Therapeutics (PRQR) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $24.9 million as the latest value for Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 20.81% to $24.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.9 million through Dec 2025, down 20.81% year-over-year, with the annual reading at $24.9 million for FY2025, 20.81% down from the prior year.
- Non-Current Deffered Revenue hit $24.9 million in Q4 2025 for ProQR Therapeutics, down from $31.4 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $66.9 million in Q4 2022 to a low of $16.8 million in Q4 2021.
- Historically, Non-Current Deffered Revenue has averaged $37.5 million across 5 years, with a median of $31.4 million in 2024.
- Biggest five-year swings in Non-Current Deffered Revenue: surged 298.15% in 2022 and later tumbled 33.83% in 2024.
- Year by year, Non-Current Deffered Revenue stood at $16.8 million in 2021, then soared by 298.15% to $66.9 million in 2022, then dropped by 28.96% to $47.5 million in 2023, then crashed by 33.83% to $31.4 million in 2024, then fell by 20.81% to $24.9 million in 2025.
- Business Quant data shows Non-Current Deffered Revenue for PRQR at $24.9 million in Q4 2025, $31.4 million in Q4 2024, and $47.5 million in Q4 2023.